TransMolecular, a biotechnology company focused on cancer treatments, has appointed Nicholas Nicolaides, PhD, as non-executive chairman of its board of directors.

Nicolaides currently serves as president and CEO of Morphotek, a subsidiary of Eisai. Prior to co-founding Morphotek, a biopharmaceutical company which develops products for treating cancer, Nicolaides was the director of research at Magainin, according to the Cambridge, Mass.-based TransMolecular.